Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) EBITDA (2025 - 2026)

Updated

Aktis Oncology (AKTS) posted EBITDA of -$35.71 million for Q3 2026, compared with -$18.35 million a year earlier.

Analysis

Aktis Oncology (AKTS) EBITDA (2025 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, EBITDA at Aktis Oncology was -$104.73 million; for FY2025, it was -$76.98 million.

  • In prior years, Aktis Oncology's EBITDA was -$54.56 million in FY2024.
  • According to Business Quant data, EBITDA for the three prior quarters was -$29.05 million (Q2 2026), -$22.58 million (Q1 2026) and -$17.39 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 8.95 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 8.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 8.16 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 7.34 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 5.99 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 4.83 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 4.20 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 7.05 Bn
10 Aktis Oncology 895.95 Mn 335.72 Mn - -35.71 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -35.71 Mn
Jun 30, 2026 -29.05 Mn
Mar 31, 2026 -22.58 Mn
Jun 30, 2025 -21.73 Mn
Mar 31, 2025 -19.51 Mn
API Access

Aktis Oncology EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=AKTS&period=max&api_key=YOUR_API_KEY